Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.46 |
| ▸ | THRA | P10827 | 4/20 | 0.45 |
| ▸ | THRB | P10828 | 4/20 | 0.45 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.42 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3580792 | 0.87 | NPSR1 (0.55) | NPSR1FFAR1FFAR4THRATHRB | |
| SCHEMBL15368850 | 0.83 | PTGS1 (0.52) | THRBHMGB1CXCL12 | |
| SCHEMBL2922404 | 0.82 | CA2 (0.53) | ACLYTHRATHRBHMGB1CXCL12 | |
| SCHEMBL19509985 | 0.79 | KDM4E (0.50) | NPSR1FFAR1FFAR4THRATHRB | |
| SCHEMBL10415447 | 0.78 | PTGS2 (0.43) | NPSR1FFAR4HMGB1CXCL12 | |
| SCHEMBL11241194 | 0.78 | NPSR1 (0.46) | NPSR1FFAR1FFAR4THRATHRB | |
| SCHEMBL10990753 | 0.78 | NPSR1 (0.46) | NPSR1FFAR1FFAR4THRATHRB | |
| SCHEMBL25217402 | 0.77 | FFAR1 (0.50) | ACLYNPSR1FFAR1THRATHRB | |
| SCHEMBL18258239 | 0.77 | NPSR1 (0.57) | NPSR1FFAR1FFAR4THRATHRB | |
| SCHEMBL24893771 | 0.77 | FFAR1 (0.59) | NPSR1FFAR1FFAR4KEAP1SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034444-A1 | SELECTED CGRP ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-10 | — | — | US | disclosed |
| US-7858622-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| US-20100004228-A1 | SELECTED CGRP ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-07 | — | — | US | disclosed |
| US-7579341-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-25 | — | — | US | disclosed |
| US-20070049581-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004228-A1 | SELECTED CGRP ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | CALCRL, CALCR, CALCA | ACLY 2816/4885NPSR1 77/4885FFAR1 644/4885 |
| US-20070049581-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | ACLY 2816/4885NPSR1 77/4885FFAR1 644/4885 |
| US-20110034444-A1 | SELECTED CGRP ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | CALCRL, CALCR, CALCA | ACLY 2816/4885NPSR1 77/4885FFAR1 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.